Axcynsis Therapeutics
- | Biotech or pharma, therapeutic R&D
Axcynsis Therapeutics develops antibody-drug conjugates (ADCs) utilizing our first-in-class ADC payload platform. Raising $40M series A. Out-licensing platform and select assets.
March 2-3, 2026・Miami, FL
March 2-3, 2026・Miami, FL
Exhibitors
-
It's the kind of meeting where biotech newsmakers can have productive dialogs with investors and other key players.
-
It's the caliber of attendees - biopharma companies on the verge of their next big step and investors looking for smart opportunities - that make BIO CEO & Investor Conference vital to the industry.
-
The BIO CEO & Investor Conference offers a collaborative forum where executives, investors and industry stakeholders can come together to learn and exchange ideas about innovation in the biopharma ecosystem.
-
The BIO CEO & Investor Conference provides timely and relevant content on the issues driving the business of biotech, along with an invaluable platform for networking and partnering.
Double Helix
)
Supporting Bank Sponsor
){kind=logo}
Premier Sponsors
)
){kind=logo}
){kind=logo}
){kind=logo}
)
Conference Sponsors
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}